Catalyst
Slingshot members are tracking this event:
UCLA sells royalty rights connected with cancer drug to Royalty Pharma for $1.14 billion
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
Royalty Pharma | Community voting in process |
Additional Information
Xtandi is based on a chemical compound that was developed at UCLA. The oral medication inhibits the androgen receptor, the engine of prostate cancer progression. Where other treatments have failed, Xtandi has extended the lives of men with metastatic castration-resistant prostate cancer. In one phase 3 clinical study of patients previously treated with chemotherapy, Xtandi reduced the risk of death by 37 percent and increased median survival by 4.8 months, compared to those who took a placebo. In a separate phase 3 clinical study of patients not previously treated with chemotherapy, Xtandi reduced the risk of death by 23 percent and increased median survival by four months.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xtandi, Prostate Cancer Medication, Research Programs, Androgen Receptor Inhibitor